Asciminib Monotherapy Study for CML-CP Patients

In this study, we are testing a medicine called asciminib to treat patients with a type of blood cancer called Chronic Myelogenous Leukemia in Chronic Phase (CML-CP). This is for people who didn't respond well to previous treatments or are newly diagnosed. The study will happen in multiple centers and will last up to 104 weeks, with additional follow-up for safety.

Three Key Points:

• The study includes three periods: screening (up to 28 days), treatment (up to 104 weeks), and a 30-day safety follow-up.
• Participants will start with a dose of 80 mg daily of asciminib, with possible dose increases based on how their cancer responds.
• Informed consent is required before participating, and eligibility criteria must be met.

Asciminib is being tested to see if it helps control CML-CP in patients who didn't respond to another type of medicine called TKI. The study will adjust doses based on how patients' bodies react to the treatment. It is important to know that participation involves regular medical assessments, and there are specific health criteria to join. Discuss with your doctor if you qualify and whether this study might benefit you.